Development of a rapid and sensitive LC-MS/MS assay for the determination of sorafenib in human plasma.
about
A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children's Oncology Group Phase I Consortium report.Pediatric phase I trial of oral sorafenib and topotecan in refractory or recurrent pediatric solid malignancies.Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer.Quantitation of sorafenib and its active metabolite sorafenib N-oxide in human plasma by liquid chromatography-tandem mass spectrometryDetermination of PF-04928473 in human plasma using liquid chromatography with tandem mass spectrometry.Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacyPopulation pharmacokinetic analysis of sorafenib in patients with solid tumours.Quantitation of VEGFR2 (vascular endothelial growth factor receptor) inhibitors--review of assay methodologies and perspectives.Phase 2 trial of sorafenib in children and young adults with refractory solid tumors: A report from the Children's Oncology Group.An LC-MS/MS method for rapid and sensitive high-throughput simultaneous determination of various protein kinase inhibitors in human plasma.Lack of association between excretion of sorafenib in sweat and hand-foot skin reactionSynergistic interactions between sorafenib and everolimus in pancreatic cancer xenografts in mice.Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy.Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas.In-vivo relation between plasma concentration of sorafenib and its safety in Chinese patients with metastatic renal cell carcinoma: a single-center clinical study.Physiologically based pharmacokinetic models for everolimus and sorafenib in mice.Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles.Biodistribution of 99mTc-sunitinib as a potential radiotracer for tumor hypoxia imaging.The plasma and cerebrospinal fluid pharmacokinetics of sorafenib after intravenous administration in non-human primates.High-performance liquid chromatographic method for the determination of sorafenib in human serum and peritoneal fluid.
P2860
Q33403207-F5284D5F-EC92-491E-81F5-AD09AB804302Q33428775-21F2D778-B104-46D1-B022-54513BD04087Q33638830-5A47613F-FB6F-48B6-9826-6DBC07BB03F2Q34209373-4F39B3A4-5FCF-42B1-9921-0F14C3C26E11Q34307325-7C27E1EE-0A83-4B65-A6FF-E3C7DB06D2ADQ35086690-1ED1EB08-D26D-4EE9-ABE6-ED9D37591B9CQ35183640-88A87FCA-B80A-414D-A9B4-D603E254F30EQ35450340-FF976E5B-6B0A-4312-9CAF-A305BF03C628Q35891218-23E0F3EE-4ADC-4EAC-B31B-A3545A8D3309Q36083906-3108C277-4408-4DEF-BDC2-CC4448AF00D5Q36525237-7E279DF7-C0DE-4252-B93D-8E6473570637Q37119137-72E2E9AA-0831-499C-AB5A-5E1BE7BF526AQ37283073-54F75E0F-9F93-40A9-93E6-3BAFE253E69CQ39555847-F59724BC-9107-4CBD-9F93-1BEA2E2FC2EAQ41092089-D7409DC2-0667-40CF-915C-D857FE867E41Q42575030-E4462F7A-0D1D-4D65-9FD6-4C5FAA8A40A9Q43841175-7AAB58DC-1E3B-46B1-9F73-7967979C4B0AQ53087435-72F1345C-D72F-45DF-A334-F753684A1308Q54633298-F8D39E93-FBED-407D-9E7B-01BA65AAF5E0Q54645380-117EB62F-739E-43B6-A5AC-D3DB2B32D77C
P2860
Development of a rapid and sensitive LC-MS/MS assay for the determination of sorafenib in human plasma.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Development of a rapid and sen ...... of sorafenib in human plasma.
@ast
Development of a rapid and sen ...... of sorafenib in human plasma.
@en
type
label
Development of a rapid and sen ...... of sorafenib in human plasma.
@ast
Development of a rapid and sen ...... of sorafenib in human plasma.
@en
prefLabel
Development of a rapid and sen ...... of sorafenib in human plasma.
@ast
Development of a rapid and sen ...... of sorafenib in human plasma.
@en
P2093
P2860
P1476
Development of a rapid and sen ...... of sorafenib in human plasma.
@en
P2093
Erin R Gardner
Jürgen Venitz
Lokesh Jain
William D Figg
William Dahut
P2860
P304
P356
10.1016/J.JPBA.2007.10.027
P577
2008-01-01T00:00:00Z